Lucira Health, Inc., a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits. It has a patent license agreement with Eiken Chemical Co., Ltd.; technical services agreement with Jabil, Inc.; and manufacturing services agreement with Jabil MSA. The company was formerly known as DiAssess Inc. and changed its name to Lucira Health, Inc. in January 2020. Lucira Health, Inc. was incorporated in 2013 and is headquartered in Emeryville, California.
IPO Year: 2021
Exchange: NASDAQ
Website: lucirahealth.com
SC 13D/A - Lucira Health, Inc. (0001652724) (Subject)
William Blair downgraded Lucira Health from Market Outperform to Market Perform
BofA Securities downgraded Lucira Health from Neutral to Underperform and set a new price target of $9.00
William Blair initiated coverage of Lucira Health with a rating of Outperform
Bank of America initiated coverage of Lucira Health with a rating of Neutral and set a new price target of $22.00
William Blair initiated coverage of Lucira Health with a rating of Outperform
BofA Securities initiated coverage of Lucira Health with a rating of Neutral and set a new price target of $22.00
Lab-quality results for both COVID-19 and Flu now available at home from one single testCOVID-19 and Flu have similar symptoms but different treatments, requiring a fast, differential test to access time-sensitive prescription treatment optionsLucira's COVID-19 & Flu Home Test demonstrated similar performance for COVID-19, Flu A and Flu B in head-to-head comparison study with highly sensitive lab-based PCR testsLucira seeks a strategic or financial partner for resumption of manufacturing and development of additional home diagnostic products EMERYVILLE, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (NASDAQ:LHDX) ("Lucira Health" or "Lucira"), a medical technology company,
EMERYVILLE, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (NASDAQ:LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company, announced today that it has filed for protection under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware. The Company further disclosed that it intends to pursue a sale of its business under Section 363 of the Bankruptcy Code, while continuing to support its customers during the Chapter 11 process. Lucira Health grew rapidly over the past several years as the COVID-19 pandemic spread throughout the world. Demand for the Company's COVID-19 test kits surged and the Company p
New partnership enables a free Sesame telehealth consultation with purchase of a Lucira at-home COVID-19 test, providing a full test-to-treat experience from the comfort of home, within two hours NEW YORK , Jan. 5, 2023 /PRNewswire/ -- Sesame, the company building a radically new healthcare system for uninsured Americans and those with high-deductible plans, and Lucira Health, Inc. ("Lucira Health" or "Lucira") today announced their national partnership to increase access to high-quality, convenient and affordable COVID-19 testing and treatment. Via Lucira Connect, a recently-launched virtual care platform, patients who purchase Lucira's COVID-19 Test can now easily learn about treatment opt
For $98 CAD Canadians will receive a free telehealth appointment included with purchase of a testLucira Connect provides lab-quality at-home test-users a telehealth visit at no additional cost, enabling Test-to-Treatment within hours for only the cost of the test, excluding prescription costs.Lucira partners with Medi-Call to give users who test positive for Covid-19 or Flu the option to access a virtual telehealth consultation to discuss their risk factors and appropriate treatment options with an independent medical professional. EMERYVILLE, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (NASDAQ:LHDX) ("Lucira Health" or "Lucira"), a medical technology company, today anno
EMERYVILLE, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (NASDAQ:LHDX) ("Lucira Health" or "Lucira"), a medical technology company, announced that it submitted an Emergency Use Authorization application to the FDA for OTC use of its simple, at-home molecular COVID-19 & Flu test. Lucira's test for COVID-19 & Flu was granted Emergency Use Authorization for Point-of-Care (POC) use in a healthcare setting in November 2022. In seeking OTC authorization, Lucira intends to make the test broadly available to consumers both online as well as in pharmacies. Lucira worked closely with the FDA to complete additional testing to demonstrate that the COVID & Flu test could be used by con
Lucira COVID-19 & Flu Test is the first and only combination over-the-counter (OTC) self-test with fast, molecular lab-quality results enabling mass testing of symptomatic residents, staff and visitors amid the aggressive COVID-19 and flu season in Canada.Lucira's 99% accurate, differential molecular test can detect Influenza A/B and all strains of COVID-19 earlier in an infection.On-site assessment (as little as 11-mins for positive status up to 30-min for result confirmation) will minimize result turnaround time and improve resident health management pathways at Loch Lomond Villa. EMERYVILLE, Calif., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (NASDAQ:LHDX) ("Lucira Health"
PCR Lab-quality NAAT/molecular test for both COVID-19 and flu from 1 shallow nasal swabPositive result as quickly as 11 minutes, negative result in 30 minutes, allowing diagnosis during patient visitEquipment-free Lucira platform requires no capital investment or calibration and permits unlimited simultaneous testingCOVID-19 and flu have similar symptoms but different treatments, requiring a fast differential test to access time-sensitive prescription treatment options Lucira's COVID-19 & Flu Test performed comparably in a head-to-head comparison study with highly sensitive lab-based PCR tests EMERYVILLE, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (NASDAQ:LHDX) ("Lucir
Digital health service offers Lucira lab-quality at-home test users a telehealth visit at no additional cost, enabling Test-to-Treatment within hours for only $29, excluding prescription costsLucira partners with Pfizer to increase awareness of the high risk factors for severe COVID-19 and treatment options through the Lucira Connect platform EMERYVILLE, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Lucira Health" or "Lucira") (NASDAQ:LHDX) today announced the launch of Lucira Connect, a new virtual care program that allows Lucira test users the ability to test, learn about treatment options, access a telehealth consultation, and if appropriate, receive a prescriptio
EMERYVILLE, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (NASDAQ:LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, today reported financial results for the third quarter ended September 30, 2022 and provided business updates. Recent Highlights Achieved net revenue of $34.4 million for the third quarter of 2022, an increase of 130% over the third quarter of 2021.Executed a marketing agreement with Pfizer to increase awareness of the risks of COVID-19 and the availability of treatment. Partnered with telehealth marketplace, Sesame Care
EMERYVILLE, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Lucira Health" or "Lucira"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, and a digital health platform that will connect patients with providers, today announced that the company will report third quarter 2022 financial results on, Monday, November 14th, 2022. Lucira's management will host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Conference Call and Webcast DetailsInvestors interested in listening to the conference call should reg
4 - Lucira Health, Inc. (0001652724) (Issuer)
4 - Lucira Health, Inc. (0001652724) (Issuer)
4 - Lucira Health, Inc. (0001652724) (Issuer)
4 - Lucira Health, Inc. (0001652724) (Issuer)
4 - Lucira Health, Inc. (0001652724) (Issuer)
4 - Lucira Health, Inc. (0001652724) (Issuer)
4 - Lucira Health, Inc. (0001652724) (Issuer)
4 - Lucira Health, Inc. (0001652724) (Issuer)
4 - Lucira Health, Inc. (0001652724) (Issuer)
4 - Lucira Health, Inc. (0001652724) (Issuer)
EMERYVILLE, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (NASDAQ:LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, today reported financial results for the third quarter ended September 30, 2022 and provided business updates. Recent Highlights Achieved net revenue of $34.4 million for the third quarter of 2022, an increase of 130% over the third quarter of 2021.Executed a marketing agreement with Pfizer to increase awareness of the risks of COVID-19 and the availability of treatment. Partnered with telehealth marketplace, Sesame Care
EMERYVILLE, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Lucira Health" or "Lucira"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, and a digital health platform that will connect patients with providers, today announced that the company will report third quarter 2022 financial results on, Monday, November 14th, 2022. Lucira's management will host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Conference Call and Webcast DetailsInvestors interested in listening to the conference call should reg
EMERYVILLE, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (NASDAQ:LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, today reported financial results for the second quarter ended June 30, 2022 and provided business updates. Recent Highlights Achieved net revenue of $26.1 million for the second quarter of 2022, an increase of 110% over the second quarter of 2021Received regulatory approval in Canada for the COVID-19 & Flu test with Self Test at Home indication and a full exemption by the New Zealand Ministry of Health for COVID-19 testSc
EMERYVILLE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Lucira Health" or "Lucira"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will report second quarter 2022 financial results on, Monday, August 15, 2022. Lucira's management will host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Conference Call and Webcast DetailsInvestors interested in listening to the conference call should register online. Participants are required to register a day in advance or
EMERYVILLE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (NASDAQ:LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, today reported financial results and provided business updates for the first quarter ended March 31, 2022. Recent Highlights Achieved net revenue of $90.5 million for the first quarter of 2022, equivalent to 97% of fiscal year 2021 net revenueRecorded first-time net income of $13.1 million Entered into a debt facility agreement up to $80 million with Silicon Valley Bank and Hercules Capital; drew down first tranche of $30
EMERYVILLE, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Lucira Health" or "Lucira"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will report first quarter 2022 financial results on Thursday, May 12, 2022. Lucira's management will host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Conference Call and Webcast DetailsThe conference call can be accessed by dialing (833) 562-0151 for participants in the U.S. or Canada and (661) 567-1232 for international cal
EMERYVILLE, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (NASDAQ:LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today reported financial results for the fourth quarter and full year ended December 31, 2021. Recent Highlights Achieved net revenue of $61.1 million for the fourth quarter of 2021, representing approximately 300% sequential growth over the preceding quarterRecorded full year revenue of $93.1 million for 2021, the Company's first full year of commercializationIncreased manufacturing output through the Dominican Repu
EMERYVILLE, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Lucira Health" or "Lucira") (NASDAQ:LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will report fourth quarter 2021 financial results on, Thursday, March 10, 2022. Lucira's management will host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Conference Call and Webcast DetailsThe conference call can be accessed by dialing (833) 562-0151 for participants in the U.S. or Canada and (661) 567-1232 for
EMERYVILLE, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (NASDAQ:LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today reported financial results for the third quarter ended September 30, 2021 and provided business updates. Highlights Recorded record-high revenue of $15.0 million for the third quarter of 2021, representing 21% sequential growth from the previous quarter of 2021Reopened online sales of its OTC LUCIRA CHECK IT COVID-19 Test Kit via the Company's website and on AmazonReceived Pandemic Special Access Route ("PSAR")
EMERYVILLE, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Lucira Health" or "Lucira"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will report third quarter 2021 financial results on, Thursday, November 11, 2021. Lucira's management will host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Conference Call and Webcast DetailsThe conference call can be accessed by dialing (833) 562-0151 for participants in the U.S. or Canada and (661) 567-1232 for internationa
15-12G - Lucira Health, Inc. (0001652724) (Filer)
8-K - Lucira Health, Inc. (0001652724) (Filer)
NT 10-Q - Lucira Health, Inc. (0001652724) (Filer)
S-8 POS - Lucira Health, Inc. (0001652724) (Filer)
S-8 POS - Lucira Health, Inc. (0001652724) (Filer)
8-K - Lucira Health, Inc. (0001652724) (Filer)
NT 10-Q - Lucira Health, Inc. (0001652724) (Filer)
8-K - Lucira Health, Inc. (0001652724) (Filer)
8-K - Lucira Health, Inc. (0001652724) (Filer)
NT 10-K - Lucira Health, Inc. (0001652724) (Filer)
The FDA provided additional information about the agency's interactions and decisions regarding the emergency use authorization (EUA) of Lucira Health Inc's (OTC: LHDXQ) COVID-19 & Flu Home test. The statement comes due to concerns about the agency's length and timing of the EUA clearance and its bankruptcy filing, which said the delay in EUA financially hit the company. In an investor report, Lucira blamed the FDA's "protracted" authorization process for its combination Covid and flu at-home test. Lucira applied to the FDA for authorization of its novel test last May and expected to receive a thumbs-up by the end of summer before the flu season started. Canada authorized Lucira's test
Failures of Covid vaccine maker Novavax Inc (NASDAQ:NVAX) and diagnostic start-up Lucira Health Inc (NASDAQ:LHDX) show that companies often succeed or fail, owing to the whims of the government. Last week, while reporting Q4 earnings, Novavax raised doubts about its ability to remain in business and announced plans to cut spending. The Covid-19 vaccine was Novavax's first and only commercial product in its 36-year history, Wall Street Journal writes. However, the product flopped after successful trials thanks to regulatory delays and manufacturing hiccups. Operation Warp Speed awarded Novavax $1.6 billion to cover testing and manufacturing costs of its experimental vaccine in exchange f
Gainers ObsEva SA (NASDAQ:OBSV) surged 86.6% to $0.1978 after dropping over 12% on Thursday. ObsEva recently announced strategic reorganization to consolidate operations in Switzerland. Altamira Therapeutics Ltd. (NASDAQ:CYTO) shares jumped 52.7% to $3.59 after the company said data from a recent peer-reviewed clinical study demonstrated Bentrio's superior nasal residence time and rheological properties. Lavoro Limited (NASDAQ:LVRO) gained 44.7% to $13.86. Lavoro and TPB Acquisition Corporation I announced completion of business combination. HUB Cyber Security (Israel) Ltd. (NASDAQ:HUBC) rose 36.6% to $1.71 after dipping 21% on Thursday. Seer, Inc. (NASDAQ:SEER) gained 35% to $5.68 a
Gainers Seer (NASDAQ:SEER) shares moved upwards by 39.4% to $5.87 during Friday's regular session. As of 12:30 EST, Seer's stock is trading at a volume of 1.6 million, which is 437.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $367.7 million. The company's, Q4 earnings came out yesterday. Bullfrog AI Hldgs (NASDAQ:BFRG) shares rose 39.18% to $3.8. As of 12:30 EST, Bullfrog AI Hldgs's stock is trading at a volume of 4.2 million, which is 1055.1% of its average full-day volume over the last 100 days. The company's market cap stands at $21.4 million. Ardelyx (NASDAQ:ARDX) stock rose 36.18% to $3.94. Trading volume for Ardelyx's s
Gainers Bullfrog AI Hldgs (NASDAQ:BFRG) stock increased by 47.6% to $4.03 during Friday's pre-market session. The company's market cap stands at $22.7 million. Rubius Therapeutics (NASDAQ:RUBY) shares moved upwards by 31.71% to $0.15. The company's market cap stands at $13.5 million. Ardelyx (NASDAQ:ARDX) shares rose 17.3% to $3.39. The market value of their outstanding shares is at $673.1 million. The company's, Q4 earnings came out yesterday. Akari Therapeutics (NASDAQ:AKTX) shares rose 16.24% to $0.38. The market value of their outstanding shares is at $28.2 million. Milestone Scientific (AMEX:MLSS) shares rose 13.92% to $0.9. The company's market cap stands at $62.8 million. Confor
Gainers Exela Technologies, Inc. (NASDAQ:XELA) shares surged 45% to $0.0701 after the company announced $51 million of new funding, amendment increases existing securitization facility to $185 million and other related transactions. BioRestorative Therapies, Inc. (NASDAQ:BRTX) shares jumped 34.7% to $3.76 after the company announced the United States Patent and Trademark Office has issued a notice of allowance for a patent application related to the Company's metabolic ThermoStem program. Diversified Healthcare Trust (NASDAQ:DHC) surged 30% to $1.21 after the company posted a profit for the fourth quarter. Desktop Metal, Inc. (NYSE:DM) gained 23% to $1.8550 after the company reported
Gainers BioRestorative Therapies (NASDAQ:BRTX) stock rose 32.4% to $3.69 during Thursday's regular session. BioRestorative Therapies's stock is trading at a volume of 28.4 million shares as of 12:30 EST. This is 189085.2% of its average full-day volume over the last 100 days. The company's market cap stands at $13.5 million. OncoSec Medical (NASDAQ:ONCS) shares rose 19.6% to $2.44. The current volume of 31.8 million shares is 2304.3% of OncoSec Medical's average full-day volume over the last 100 days (last updated at 12:30 EST). The company's market cap stands at $7.2 million. Biophytis (NASDAQ:BPTS) stock moved upwards by 19.56% to $0.5. The current volume of 7.6 million shares is 1275.2
Gainers Biophytis (NASDAQ:BPTS) stock moved upwards by 34.1% to $0.56 during Thursday's pre-market session. The company's market cap stands at $11.4 million. OncoSec Medical (NASDAQ:ONCS) shares rose 32.35% to $2.7. The market value of their outstanding shares is at $8.0 million. Avenue Therapeutics (NASDAQ:ATXI) stock increased by 30.35% to $1.46. The market value of their outstanding shares is at $8.0 million. BioRestorative Therapies (NASDAQ:BRTX) shares increased by 26.52% to $3.53. The company's market cap stands at $12.9 million. Apexigen (NASDAQ:APGN) shares rose 10.46% to $0.95. The company's market cap stands at $23.4 million. Chimerix (NASDAQ:CMRX) shares increased by 9.96% t
Gainers MMTec, Inc. (NASDAQ:MTC) rose 76% to $2.78 in pre-market trading after jumping 37% on Wednesday. On February 22, MMTec raised $32 million by issuing an unsecured senior convertible promissory note worth $40 million to a non-U.S. investor under a securities purchase deal. Blue Star Foods Corp. (NASDAQ:BSFC) rose 71.7% to $0.28 in pre-market trading. Blue Star Foods recently priced a $1.8 million underwritten public offering of common stock. Lucira Health, Inc. (NASDAQ:LHDX) rose 15.2% to $0.91 in pre-market trading after dropping 15% on Wednesday. Lucira Health recently announced FDA authorization for its at-home combination COVID-19 & flu test. Salesforce, Inc. (NYSE:CRM) rose
Gainers Reata Pharmaceuticals Inc (NASDAQ:RETA) shares jumped 171.5% to $84.67 after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia. OncoSec Medical Incorporated (NASDAQ:ONCS) jumped 122.7% to $2.4050 after the company requested withdrawal of registration statement. The company said it has opted not to pursue offering thereby at this time. HPX Corp. (NYSE:HPX) gained 51.3% to $14.96. Lucira Health, Inc. (NASDAQ:LHDX) gained 31% to $1.2250. Lucira Health recently announced FDA authorization for its at-home combination COVID-19 & flu test. Nerdy, Inc. (NYSE:NRDY) surged 29.6% to $3.2550 following better-than-expected Q4 results. Helbiz Inc (NAS